New depression pill shows promise in Mid-Stage trial
NCT ID NCT07226661
First seen Nov 10, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study tests whether a new drug called SPN-821 can help adults with major depression when added to their current antidepressant. About 230 people will receive either SPN-821 or a placebo for 29 days. The main goal is to see if the drug reduces depression symptoms more than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Collaborative Neuroscience Network
RECRUITINGGarden Grove, California, 92845, United States
Conditions
Explore the condition pages connected to this study.